Form 4: United Therapeutics COO Sells Shares via 10b5-1 Plan
Insider Transaction Report
United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned stock option exercises and subsequent sales of common stock totaling 22,500 shares.
Summary
- Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported transactions involving the exercise of stock options and the sale of common stock.
- On November 10, 2025, Benkowitz exercised 14,625 stock options at an exercise price of $135.42 per share and simultaneously sold the resulting 14,625 common shares at $452.0937 per share.
- Additionally, on the same date, he exercised 7,875 stock options at an exercise price of $146.03 per share and sold the resulting 7,875 common shares at $452.0397 per share.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
- Following these transactions, Benkowitz directly owns 2,648 shares of common stock.
- He also beneficially owns 26,625 derivative securities (stock options) through one trust and 2,625 derivative securities (stock options) through another trust.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider transaction (exercise and sale of stock options) which is generally considered neutral in terms of company-specific sentiment. The 10b5-1 plan mitigates potential negative interpretations of insider selling.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations and demonstrates adherence to corporate governance best practices.
- The significant difference between the exercise prices ($135.42 and $146.03) and the sale prices ($452.0937 and $452.0397) indicates substantial gains for the reporting person, reflecting positive past performance of the company's stock.
Negatives
- Insider selling, even when pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- The exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025.
Industry Context
This filing is a routine insider transaction disclosure and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Establishment and Execution | The reporting person entered into a Rule 10b5-1 trading plan on June 3, 2025, under which the reported stock option exercises and share sales were executed. This plan allows insiders to sell shares at a pre-determined time or price, providing an affirmative defense against insider trading allegations. | 06/03/2025 | Enhances transparency and reduces the perception of opportunistic insider trading, aligning with good corporate governance practices. |
Related Party Transactions
- The transactions involved shares held in two separate trusts. One trust is beneficially owned by the Reporting Person, with the Reporting Person and his spouse as co-trustees having shared investment and voting power. The other trust is beneficially owned by the Reporting Person's family members, with the Reporting Person having sole investment and voting power.
Stakeholder Impact
- Shareholders: May interpret the insider sale as a signal, though the pre-planned nature via a 10b5-1 plan typically mitigates concerns about negative company outlook. It represents a diversification or liquidity event for the executive.
- Employees: No direct impact mentioned, but executive transactions can sometimes influence morale or perception of leadership's commitment.
Key Dates
| Date | Description |
|---|---|
| 03/15/2023 | Date stock options became exercisable |
| 06/03/2025 | Date Rule 10b5-1 trading plan was entered into by the reporting person |
| 11/10/2025 | Date of stock option exercises and subsequent sales of common stock |
| 11/12/2025 | Signature date of the reporting person's representative |
| 03/15/2026 | Expiration date of stock options |
Recommendation
holdThe filing details a pre-planned insider sale of shares by the President and COO, Michael Benkowitz, executed under a Rule 10b5-1 trading plan. Such transactions are typically for personal financial management, diversification, or liquidity purposes and are not usually indicative of a change in the company's fundamental prospects or a negative outlook. The existence of a 10b5-1 plan mitigates the negative signal often associated with insider selling. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it does not present new information that would fundamentally alter the investment thesis for United Therapeutics.
Keywords
UTHR, United Therapeutics, Michael Benkowitz, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Equity Sales, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.